knowledge -WSS

knowledge

author：focus 2025-09-28 22:28:57 - browse：767

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

LONDON — A U.K. government agency on Tuesday said that it won’t recommend Eli Lilly’s Mounjaro — part of a new class of medications that help patients lose weight — for people with type 2 diabetes without additional evidence.

Mounjaro, also known as tirzepatide, has U.S. approval for type 2 diabetes and is expected to win the regulatory green light for obesity later this year. It is one of several medications, along with Wegovy and Ozempic from Novo Nordisk, that have shown dramatic weight loss results, creating a surge in demand and blockbuster sales expectations.

But in draft guidance, the U.K.’s National Institute for Health and Care Excellence, which assesses the cost-effectiveness of medications, said it had asked Lilly for more data “to address the uncertainties in the clinical evidence, when compared to all relevant alternative treatments.” NICE recommendations are used by the National Health Service to determine whether to provide certain medications.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： CDC Director Mandy Cohen on transparency, trust, and health

WSS

What health policies could hitch a ride on a spending bill?

NIH chief: government has fallen behind pharma on clinical trials

Senate panel puts off hardest PBM reforms for another day

Democrats decry new health bill for going easy on private equity

Readout LOUD Podcast: Lilly's obesity drug, the power of radiation

Democrats decry new health bill for going easy on private equity

Wikipedia

knowledge

hotspot

Hepatitis C has a cure — but many Americans still lack access to it

What causes rare myocarditis in young men after Covid vaccines?

Hollywood unions extend contract negotiations for actors

What to watch for from Zogenix and Amicus clinical trials

Bright Health sells Medicare Advantage business to Molina

How state and local governments are sidelining science

Medical leaders decry Supreme Court decision on affirmative action

Device maker Teleflex to acquire urology company for $600M

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

CVS, Rite Aid closures threaten to worsen pharmacy deserts

focus

Will the FTC rein in IQVIA's health data empire?

Type 2 diabetes prevention programs work at large scale: study

Type 2 diabetes prevention programs work at large scale: study

UHS says company favors patients whose insurance pays more

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

'Investigate these claims': UFO transparency at center of House hearing

explore

explore

hotspot

explore